1. Scrip
  2. >>Business

Merck Pays $2.75bn To Access VelosBio’s ROR1-Targeting ADCs

Private Biotech Raised $137m In Venture Capital In July

 
• By Mandy Jackson

Merck continues its cancer deal streak, purchasing a pipeline of antibody-drug conjugates and bispecific antibodies against receptor tyrosine kinase-like orphan receptor 1 (ROR1). 

White jigsaw puzzle on blue background
Merck & Co. added assets to its oncology pipeline with the VelosBios buy • Source: Shutterstock

Merck & Co., Inc. continued its business development push in oncology on 5 November with the announcement that it will pay $2.75bn in cash for VelosBio Inc., a privately held developer of antibody-drug conjugates and bispecific antibodies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in a deal that is expected to close by the end of 2020.

San Diego-based VelosBio’s lead ADC candidate VLS-101 is in Phase I for the treatment of hematological malignancies and the first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business